46 records found.
May 16, 2019
Pulmatrix Announces Leadership Change
May 15, 2019
Pulmatrix Reports Q1 2019 Results
Apr 15, 2019
Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole(TM)
Apr 08, 2019
Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering
Apr 03, 2019
Pulmatrix, Inc. Announces Pricing of $14.4 Million Upsized Public Offering
Apr 01, 2019
Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole
Mar 14, 2019
Pulmatrix to Participate in Upcoming Investor Conferences
Feb 19, 2019
Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline
Feb 12, 2019
Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs
Feb 08, 2019
Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market
Feb 07, 2019
Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study
Feb 06, 2019
Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1
Feb 05, 2019
Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split
Feb 05, 2019
Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock
Jan 31, 2019
Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock
Jan 28, 2019
Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock
Jan 28, 2019
Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock
Nov 29, 2018
Pulmatrix Announces $3.0 Million Registered Direct Offering
Nov 21, 2018
Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Nov 15, 2018
Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology

Pages